The U.S. Just Blinked on Hep B — While the Rest of the World Didn’t

Hook

For more than three decades, the U.S. vaccinated every newborn against hepatitis B within 24 hours of birth.

This week, that universal recommendation ended.

Globally, almost no one else is changing course.

What Changed in the U.S.

The CDC approved a revision to the childhood immunization schedule that:

removes the universal birth-dose recommendation
keeps immediate birth dosing when the mother is hepatitis B–positive or status is unknown
allows delayed timing for infants born to hepatitis B–negative mothers

This isn’t a toxicity story. It’s a policy story.

The global context (the part headlines skip)

Why the Hepatitis B Birth Dose Exists

Worldwide:

many countries still run a universal birth dose strategy
WHO guidance continues to emphasize early protection, especially where prevalence is moderate/high or system gaps exist

U.S. vs EU vs WHO-world (simple comparison)

Region / System	Typical approach	What it assumes
United States (2025)	Risk-based birth dose	Strong screening + strong follow-up
EU/EEA	Mixed (targeted in some, universal birth dose in a few)	Policy varies with prevalence + infrastructure
WHO “default” global strategy	Universal birth dose emphasized	Systems fail sometimes — plan for it

FAQ (reader-facing)

Q: Is the hepatitis B vaccine still recommended for children?
A: Yes — the debate is about timing, not whether kids should be vaccinated.

Q: Why do so many countries keep the birth dose?
A: Because early infection is uniquely consequential and early protection is uniquely effective — and because systems aren’t perfect.

Q: Is a negative maternal test a guarantee?
A: It lowers risk a lot, but it doesn’t eliminate real-world failure modes (late care, errors, missing records).

Closing

The U.S. didn’t discover something new about hepatitis B.

It decided it trusts its infrastructure more than its safeguards.

Most of the world still doesn’t.